Skin Hyperpigmentation in Iron Overload
The bronze-colored skin hyperpigmentation in iron overload should be described as "greyish-brown discoloration" or "skin pigmentation," not strictly as "bronze," according to the most recent authoritative guidelines. 1
Terminology and Clinical Description
The 2022 EASL Clinical Practice Guidelines on Haemochromatosis specifically characterize the typical skin appearance as "greyish-brown discoloration" 1. This is the most precise and clinically accurate descriptor based on current guideline recommendations.
Historical Context vs. Current Terminology
While the term "bronze diabetes" has been historically used to describe the classic triad of cirrhosis, diabetes, and skin pigmentation in fully established hemochromatosis 2, this represents an older clinical description from when patients presented with advanced disease. The 2011 AASLD guidelines note that this classic presentation is now less common, as most patients are identified earlier through screening 2.
Key Clinical Points
- Color description: The skin changes are more accurately described as greyish-brown rather than purely bronze 1
- Distribution: Hyperpigmentation typically occurs in sun-exposed regions 3
- Mechanism: Results from excessive iron deposition in skin parenchymal cells, combined with increased melanin production 4, 5
- Prevalence in modern practice: Skin pigmentation was present in 75-82% of symptomatic patients in older series 2, but only 5-9% in more recently diagnosed patients identified through screening 2
Clinical Significance
Skin pigmentation is responsive to phlebotomy treatment 2, making it one of the reversible manifestations when iron overload is addressed. This distinguishes it from irreversible complications like established cirrhosis or arthropathy.
Important Caveat
The presence of skin hyperpigmentation indicates advanced disease with significant iron accumulation. In contemporary practice, most patients with hereditary hemochromatosis are diagnosed before developing visible skin changes, emphasizing the importance of early biochemical screening rather than waiting for clinical manifestations 1, 2.